Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb 27;2(2):e29.
doi: 10.1038/psp.2013.5.

Modeling and simulation in clinical pharmacology and dose finding

A Staab  1 , E Rook, M Maliepaard, L Aarons, C Benson
Affiliations

Modeling and simulation in clinical pharmacology and dose finding

A Staab et al. CPT Pharmacometrics Syst Pharmacol. .

Abstract

The breakout session 2 of the European Medicines Agency/European Federation of Pharmaceutical Industries and Associations Modeling and Simulation (M&S) workshop focused on two topics: when and how M&S should be used and would be accepted by the authorities for the dose-regimen selection; and when and how M&S can be applied to register a dosing regimen without the need for a specific study. Each topic was introduced by an industry and regulatory perspective, followed by case examples for illustration (Table 1).CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e29; doi:10.1038/psp.2013.5; advance online publication 27 February 2013.

PubMed Disclaimer

References

    1. Stone J.A.et al. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry J. Clin. Pharmacol. 5020S–30S.2010 - PubMed
    1. Lalonde R.L.et al. Model-based drug development Clin. Pharmacol. Ther. 8221–32.2007 - PubMed
    1. Jönsson S., Henningsson A., Edholm M., &, Salmonson T. Role of modelling and simulation: a European regulatory perspective. Clin. Pharmacokinet. 2012;51:69–76. - PubMed
    1. Lee J.Y.et al. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008 Clin. Pharmacokinet. 50627–635.2011 - PubMed
    1. European Medicines Agency Draft concept paper: Concept paper on extrapolation of efficacy and safety in medicine development . < http://www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideli... > Accessed 1 October 2012.